Leaflet LAGEVRIO 200mg hard capsules
Indicated for: COVID-19
Route of administration: oral
Substance: molnupiravir (antiviral)
ATC: J05AB18 (Antiinfectives for systemic use | Direct acting antivirals | Nucleosides and nucleotides excl. reverse transcriptase inhibitors)
Dose adjustment may be needed in kidney disease.
This medicine may have important interactions with other medicines.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Molnupiravir is an antiviral medication used for the treatment of COVID-19 in patients with mild to moderate disease who are at high risk of progressing to severe illness. It works by inhibiting the replication of the SARS-CoV-2 virus, thereby reducing viral load.
The medication is taken orally, usually twice daily for five days. It is effective in reducing the risk of hospitalization and death in high-risk patients.
Side effects may include nausea, diarrhea, dizziness, and headache. Currently, its use is limited to certain patient groups, and its long-term safety is still under investigation.
Consult your doctor to discuss whether Molnupiravir is suitable for you. It is important to follow the prescribed dosage and adhere to all medical recommendations.
General data about LAGEVRIO 200mg
- Substance: molnupiravir
- Product code: W530950089
- Concentration: 200mg
- Pharmaceutical form: hard capsules
- Quantity: 40
- Product type: Generic medicine
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
